Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119

Benzinga Newsdesk www.benzinga.com Negative 51.4%

Neg 51.4% Neu 0% Pos 0%

Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and lowers the price target from $124 to $119.